Terms: = Prostate cancer AND FOXP1, MGC12942, 27086, ENSG00000114861, hFKH1B, MGC99551, FLJ23741, QRF1, 12CC4, HSPC215, MGC88572
20 results:
1. Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes.
Kumar S U; Balasundaram A; Cathryn R H; Varghese RP; R S; R G; Younes S; Zayed H; Doss C GP
Comput Biol Med; 2022 Sep; 148():105701. PubMed ID: 35753820
[TBL] [Abstract] [Full Text] [Related]
2. Weighted correlation network analysis revealed novel long non-coding RNAs for colorectal cancer.
Chodary Khameneh S; Razi S; Shamdani S; Uzan G; Naserian S
Sci Rep; 2022 Feb; 12(1):2990. PubMed ID: 35194111
[TBL] [Abstract] [Full Text] [Related]
3. Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition.
Raspin K; O'Malley DE; Marthick JR; Donovan S; Malley RC; Banks A; Redwig F; Skala M; Dickinson JL; FitzGerald LM
Prostate; 2022 Apr; 82(5):540-550. PubMed ID: 34994974
[TBL] [Abstract] [Full Text] [Related]
4. foxp1 and NDRG1 act differentially as downstream effectors of RAD9-mediated prostate cancer cell functions.
Panigrahi SK; Broustas CG; Cuiper PQ; Virk RK; Lieberman HB
Cell Signal; 2021 Oct; 86():110091. PubMed ID: 34298089
[TBL] [Abstract] [Full Text] [Related]
5. Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets.
Spethmann T; Böckelmann LC; Labitzky V; Ahlers AK; Schröder-Schwarz J; Bonk S; Simon R; Sauter G; Huland H; Kypta R; Schumacher U; Lange T
Mol Oncol; 2021 Jul; 15(7):1956-1969. PubMed ID: 33533127
[TBL] [Abstract] [Full Text] [Related]
6. Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for foxp1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation.
Mulvaney EP; O'Sullivan ÁG; Eivers SB; Reid HM; Kinsella BT
Exp Mol Pathol; 2019 Oct; 110():104277. PubMed ID: 31271729
[TBL] [Abstract] [Full Text] [Related]
7. Deletion of 3p13-14 locus spanning foxp1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis.
Hieronymus H; Iaquinta PJ; Wongvipat J; Gopalan A; Murali R; Mao N; Carver BS; Sawyers CL
Nat Commun; 2017 Oct; 8(1):1081. PubMed ID: 29057879
[TBL] [Abstract] [Full Text] [Related]
8. Regulated expression of the TPβ isoform of the human T prostanoid receptor by the tumour suppressors foxp1 and NKX3.1: Implications for the role of thromboxane in prostate cancer.
O'Sullivan AG; Eivers SB; Mulvaney EP; Kinsella BT
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3153-3169. PubMed ID: 28890397
[TBL] [Abstract] [Full Text] [Related]
9. [IDENTIFICATION OF A NEW DIAGNOSTIC MARKERS OF PROSTATIC cancer, USING NOTI-MICROCHIPS].
Vozianov SO; Kashuba VI; Grygorenko VM; Gordiyuk VV; Danylets RO; Bondarenko YM; Vikarchuk MV
Klin Khir; 2016 Apr; (4):54-7. PubMed ID: 27434957
[TBL] [Abstract] [Full Text] [Related]
10. Identification of Novel Epigenetic Markers of prostate cancer by NotI-Microarray Analysis.
Dmitriev AA; Rosenberg EE; Krasnov GS; Gerashchenko GV; Gordiyuk VV; Pavlova TV; Kudryavtseva AV; Beniaminov AD; Belova AA; Bondarenko YN; Danilets RO; Glukhov AI; Kondratov AG; Alexeyenko A; Alekseev BY; Klein G; Senchenko VN; Kashuba VI
Dis Markers; 2015; 2015():241301. PubMed ID: 26491211
[TBL] [Abstract] [Full Text] [Related]
11. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With prostate cancer.
Yamoah K; Johnson MH; Choeurng V; Faisal FA; Yousefi K; Haddad Z; Ross AE; Alshalafa M; Den R; Lal P; Feldman M; Dicker AP; Klein EA; Davicioni E; Rebbeck TR; Schaeffer EM
J Clin Oncol; 2015 Sep; 33(25):2789-96. PubMed ID: 26195723
[TBL] [Abstract] [Full Text] [Related]
12. Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome.
Cho H; Herzka T; Stahlhut C; Watrud K; Robinson BD; Trotman LC
Methods; 2015 May; 77-78():197-204. PubMed ID: 25592467
[TBL] [Abstract] [Full Text] [Related]
13. Integrative analysis of foxp1 function reveals a tumor-suppressive effect in prostate cancer.
Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Takahashi S; Homma Y; Urano T; Aburatani H; Inoue S
Mol Endocrinol; 2014 Dec; 28(12):2012-24. PubMed ID: 25329375
[TBL] [Abstract] [Full Text] [Related]
14. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract] [Full Text] [Related]
15. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U
J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350
[TBL] [Abstract] [Full Text] [Related]
16. cancer genetics and genomics of human FOX family genes.
Katoh M; Igarashi M; Fukuda H; Nakagama H; Katoh M
Cancer Lett; 2013 Jan; 328(2):198-206. PubMed ID: 23022474
[TBL] [Abstract] [Full Text] [Related]
17. Integrative genomic profiling of human prostate cancer.
Taylor BS; Schultz N; Hieronymus H; Gopalan A; Xiao Y; Carver BS; Arora VK; Kaushik P; Cerami E; Reva B; Antipin Y; Mitsiades N; Landers T; Dolgalev I; Major JE; Wilson M; Socci ND; Lash AE; Heguy A; Eastham JA; Scher HI; Reuter VE; Scardino PT; Sander C; Sawyers CL; Gerald WL
Cancer Cell; 2010 Jul; 18(1):11-22. PubMed ID: 20579941
[TBL] [Abstract] [Full Text] [Related]
18. foxp1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract] [Full Text] [Related]
19. Expression of the forkhead transcription factor foxp1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
[TBL] [Abstract] [Full Text] [Related]
20. The foxp1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p.
Banham AH; Beasley N; Campo E; Fernandez PL; Fidler C; Gatter K; Jones M; Mason DY; Prime JE; Trougouboff P; Wood K; Cordell JL
Cancer Res; 2001 Dec; 61(24):8820-9. PubMed ID: 11751404
[TBL] [Abstract] [Full Text] [Related]
